Connecticut’s governor has signed a bill to expand a pilot program explore the therapeutic potential of psychedelics such as psilocybin and MDMA.
The legislation, sponsored by the Joint Committee on Public Health, cleared the House of Representatives on a 122-27 vote last month, after passing the Senate by a unanimous 35-0 vote in April.
Gov. Ned Lamont (D) signed it into law Thursday.
The new law builds on it an existing psychedelic-assisted therapy program involving military veterans and first responders who choose to participate in clinical trials.
It also repeals and replaces existing statute, adults 18 or older who meet clinical eligibility criteria established by the medical school institutional review board selected to administer the pilot program. may be eligible for psychedelic treatment in a clinical settingwith researchers responsible for studying the effectiveness of novel therapeutics.
It also removes existing language specifying that the pilot program must end upon approval of federal approval of psilocybin or MDMA by the Drug Enforcement Administration (DEA) or a successor agency.
Finally, he calls the state Department of Mental Health and Addiction Services to create and facilitate the program by January 2023.
Rep. Cristin McCarthy Vahey (D) said before the House vote that the legislation is “critically important,” citing recent moves by federal officials. accelerate research and therapeutic access to psychedelics after President Donald Trump signed an executive order on the matter in April
“If fast track is successful and these drugs are approved, our study will be terminated, and as a result, we will not be able to continue the study and lose the benefit of the investment we have already made as a state, but will also make us ineligible for those federal matching funds,” he said on the floor.
According to the Connecticut bill, SB 191officials to “establish, within available appropriations, a pilot psychedelic-assisted therapy program to be administered by a state medical school.” That program will “provide MDMA or psilocybin-assisted therapy to qualified patients as part of a research program approved by the Federal Food and Drug Administration,” or FDA, it says.
Rep. Nicole Klarides-Ditria (R) also spoke in support of the legislation, saying “this expanded access is groundbreaking research. It’s evidence-based research. Mental health and treatment are critical to the state of Connecticut.”
“Extending it to anyone over the age of 18 will really help us continue this pilot program,” he said.
To that point, McCarthy Vahey said that due to the constraints of the current structure there have been difficulties in recruiting enough participants.
“The current pilot is very focused and tailored. And in fact, the priority will be to make veterans, first responders and our direct health care workers the focus of the research,” he said. “But they tell us they’re having a little difficulty recruiting some people. The goal is to get to a cohort of 50, so this will give them a little bit of a chance to do that.”
Rep. Dave Yaccarino (R) said he voted against the original psychedelic program legislation a few years ago, but has since heard of studies showing benefits “for the men and women who come out of combat, our firefighters, our police officers who witness tragic events.”
“If this helps, and it’s controlled, I think you should accept it,” he said.
—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.
Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—
Meanwhile, last year The Connecticut House of Representatives passed a bill to decriminalize psilocybin for adults—Despite being asked if the governor would accept it after rejecting a previous version of the reform measure.
This was the third consecutive session in which Connecticut lawmakers worked to decriminalize psilocybin. in 2023, the reform measure cleared the House but it did not move from the Senate. The The Judiciary Committee also approved a version in 2024.
Lamont also signed a major budget bill in 2022 that included provisions for statehood. providing some patients with access to psychedelic-assisted treatment Using substances like MDMA and psilocybin.
Lawmakers also sent the governor’s legislation this session address the THC potency limit of the cannabis product.
Separately, legislation allow the use of medical marijuana in health care facilities by some eligible patients such as hospitals, nursing homes and hospices received a committee hearing but did not move forward.
user photo Mark Groeneveld.